Body contouring device maker sees accelerating demand from practices treating post-weight-loss patients on semaglutide.
Apyx Medical reported that demand for its Renuvion helium plasma and AYON body contouring systems is accelerating, driven by the surge in GLP-1 agonist use. Patients on semaglutide and tirzepatide who achieve rapid weight loss are increasingly seeking skin tightening and body sculpting—a shift that plays directly to Renuvion's strengths in minimally invasive body contouring.
The trend validates a thesis that emerged in 2024: GLP-1 disruption, while initially damaging to facial injectables, is creating new revenue streams in body procedures. Renuvion's radiofrequency-assisted liposuction and skin-tightening mechanism is particularly suited to post-weight-loss patients seeking non-surgical alternatives to traditional body lift surgery.
Apyx sees GLP-1 boom fueling demand for Renuvion and AYON body contouring systems.
For practice owners considering device investment, Apyx's guidance suggests that body contouring will be a growth category through 2026. The capital requirement is higher than injectables, but patient volume and procedure pricing in this segment remain strong.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
